Electra Therapeutics Inc (ETRA)

CUSIP: 284825106 | NYSE | 4 institutional holders

Compare Detailed Historical Funds Options 13D/13G Peers Targeting Trading Summary Profile

Beneficial Ownership — 13D / 13G

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

Holder	Shares	% of Class	Change	Event Date	vs 13F
13GDr. Beth C. Seidenberg with Westlake BioPartners GP I, LLC, Westlake BioPartners Fund I, L.P., Westlake BioPartners GP II, LLC, +1 more	6,347,539	10.1%	New 5%+ stake	Sep 30, 2026	No 13F filer matched
13D Orbimed Advisors LLC

Institutional Holders — Q3 2026

Sort by

Sanofi2,461,948

4.4% of portfolio$27.7M

Jefferies Financial Group Inc.2,244,333

0.2% of portfolio$25.2M

Monashee Investment Management LLC100,000

3.4% of portfolio$1.1M

Y-Intercept (Hong Kong) Ltd21,103

0.0% of portfolio$237.4K

				Style	Turnover	Location	Filed
Sanofi	2,461,948	$27.7M	4.4%	Deep Value	Very Low	Paris, India	2026-11-05
Jefferies Financial Group Inc.	2,244,333	$25.2M	0.2%	Core	Very High	New York, NY	2026-11-05
Monashee Investment Management LLC	100,000	$1.1M	3.4%	GARP	Very High	Boston, MA	2026-11-06
Y-Intercept (Hong Kong) Ltd	21,103	$237.4K	0.0%	Value	Very High	Hong Kong, South Korea	2026-10-16

13GDr. Beth C. Seidenberg6,347,539

10.1% of class · Sep 30, 2026New 5%+ stake

with Westlake BioPartners GP I, LLC, Westlake BioPartners Fund I, L.P., Westlake BioPartners GP II, LLC, +1 more

No 13F filer matched

13D Orbimed Advisors LLC6,885,170

11.0% of class · Sep 21, 2026New 5%+ stake

with Orbimed Capital GP VII LLC, OrbiMed Genesis GP LLC

Not yet in a 13F

13GRedmile Group, LLC5,462,881

8.7% of class · Sep 21, 2026New 5%+ stake

with Redmile Biopharma Investments II, L.P.

No 13F filer matched

13GLSP 7 Management B.V.3,795,281

6.0% of class · Sep 21, 2026New 5%+ stake

No 13F filer matched